sy-5609 Publications

TOLERABILITY AND PRELIMINARY ACTIVITY OF THE POTENT, SELECTIVE, ORAL CDK7 INHIBITOR SY-5609 IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ADVANCED HORMONE RECEPTOR-POSITIVE (HR+), HER2- BREAST CANCER (BC)

JURIC D, et al. ASCO ANNUAL MEETING. June 2023
ABSTRACT NUMBER: 3081

PHASE 1/1B STUDY OF SY-5609, A SELECTIVE AND POTENT CDK7 INHIBITOR, IN ADVANCED SOLID TUMORS AND IN 2L/3L PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IN COMBINATION WITH GEMCITABINE +/- NAB-PACLITAXEL

BASHIR B, et al. ASCO ANNUAL MEETING. June 2023
Abstract Number: 3080

SY-5609, A POTENT AND SELECTIVE CDK7 INHIBITOR, POTENTIATES BTK INHIBITOR ACTIVITY IN MANTLE CELL LYMPHOMA PRECLINICAL MODELS

JOHANNESSEN L, et al. ASH ANNUAL MEETING. 2021
Abstract Number: 1205

DISCOVERY OF SY-5609: A SELECTIVE, NONCOVALENT INHIBITOR OF CDK7

MARINEAU j, et al. J of Medicinal Chemistry. November 2021
DOI: 10.1021/acs.jmedchem.1c01171

TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF SY-5609, A HIGHLY POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS

Sharma M, et al. ESMO congress. 2021
Oral Presentation
Abstract Number: 518MO

SY-5609, A HIGHLY POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, EXHIBITS ROBUST ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF KRAS MUTANT CANCERS AS A SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY

Henry S, et al. ESMO Congress. 2021
Abstract Number: 13P

PRECLINICAL EVALUATION OF INTERMITTENT DOSING REGIMENS ON ANTITUMOR AND PD ACTIVITY OF SY-5609, A POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, IN OVARIAN CANCER XENOGRAFTS

Johannessen L, et al. ESMO Congress. 2021
Abstract Number: 14P

EARLY EVIDENCE OF DOSE-DEPENDENT PHARMACODYNAMIC ACTIVITY FOLLOWING TREATMENT WITH SY-5609, A HIGHLY SELECTIVE AND POTENT ORAL CDK7 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS

Papadopoulos K, et al. EORTC-NCI-AACR Symposium. 2020
Abstract Number: 180

ACTIVITY OF SY-5609, AN ORAL, NONCOVALENT, POTENT, AND SELECTIVE CDK7 INHIBITOR, IN PRECLINICAL MODELS OF COLORECTAL CANCER

Johannessen L, et al. ASCO Annual Meeting. 2020
Abstract Number: 3585

FIRST-IN-HUMAN PHASE I STUDY OF SY-5609, AN ORAL, POTENT, AND SELECTIVE NONCOVALENT CDK7 INHIBITOR, IN ADULT PATIENTS WITH SELECT ADVANCED SOLID TUMORS

Papadopoulos K, et al. ASCO Annual Meeting. 2020 
Abstract Number: TPS3662

PRECLINICAL EVALUATION OF PK, PD, AND ANTI-TUMOR ACTIVITY OF THE ORAL, NON-COVALENT, POTENT AND HIGHLY SELECTIVE CDK7 INHIBITOR, SY-5609, PROVIDES RATIONALE FOR CLINICAL DEVELOPMENT IN MULTIPLE SOLID TUMOR INDICATIONS

JOHANNESSEN L, et al. EORTC-NCI-AACR MOLECULAR TARGETS AND CANCER SYMPOSIUM. 2019
ABSTRACT NUMBER: C091

SY-5609, AN ORALLY AVAILABLE SELECTIVE CDK7 INHIBITOR, DEMONSTRATES BROAD ANTI-TUMOR ACTIVITY IN VIVO

Hu S, et al. AACR Annual Meeting. 2019
Abstract Number: 4421

AN ORAL AND SELECTIVE CDK7 INHIBITOR DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN BREAST AND OVARIAN CANCER MODELS

Shanhu Hu, Jason Marineau, Michael Bradley, Kristin Hamman, Sydney Alnemy, Danielle Smith, John Carulli, Claudio Chuaqui
30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Abstract Number 96
2018